Because subtherapeutic dosing sits below the FDA-approved starting dose and lacks randomized trial support, providers will explain the trade-offs honestly: the appeal (slower onset, reduced GI side-effect reports, lower cost) and the limits (no efficacy guarantee, no proven cardiovascular benefit at microdose levels, ongoing safety monitoring still required)
The KES resulted in block effect is not limited to larger fibers but all fiber types, and responses are recoverable with proper stimulation dose range and recovery time (Pelot and Grill 2020)
& Tomlinson, J
The message of the article is to assess responsibly, know regulations, and provide factual information through available evidence
However, increased bioavailability does not always translate into clinical efficacy, especially in PCOS, where phenotype-specific therapeutic targeting is required because of disease heterogeneity (metabolic vs
The starting dose depends on your current treatment and will be determined by your doctor, who will gradually adjust it based on effectiveness and tolerability. What are the common side effects and what serious risks exist
